Mesoblast (NASDAQ:MESO) Sees Large Volume Increase

Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 5,883,669 shares changed hands during mid-day trading, an increase of 210% from the previous session's volume of 1,896,448 shares.The stock last traded at $6.53 and had previously closed at $5.01.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on MESO shares. StockNews.com upgraded Mesoblast from a "sell" rating to a "hold" rating in a report on Monday, March 4th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research note on Friday, January 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $13.67.

Mesoblast Trading Up 21.4 %

The company has a market cap of $617.30 million, a price-to-earnings ratio of -5.43 and a beta of 3.59. The company has a fifty day moving average price of $2.31 and a two-hundred day moving average price of $2.31.

Institutional Investors Weigh In On Mesoblast

Institutional investors have recently bought and sold shares of the business. State Street Corp bought a new position in shares of Mesoblast during the 1st quarter worth about $757,000. BlackRock Inc. lifted its stake in Mesoblast by 20.8% during the first quarter. BlackRock Inc. now owns 864,638 shares of the company's stock worth $3,649,000 after purchasing an additional 149,023 shares during the period. Millennium Management LLC acquired a new stake in Mesoblast during the fourth quarter valued at approximately $344,000. Prosperity Wealth Management Inc. bought a new stake in shares of Mesoblast in the 3rd quarter valued at approximately $79,000. Finally, Jane Street Group LLC bought a new stake in shares of Mesoblast in the 4th quarter valued at approximately $187,000. Institutional investors and hedge funds own 1.43% of the company's stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.